- Home
- EDUC vs APRE Comparison
EDUC vs APRE Comparison
Compare EDUC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- APRE
- Stock Information
- Founded
- EDUC 1965
- APRE 2006
- Country
- EDUC United States
- APRE United States
- Employees
- EDUC N/A
- APRE N/A
- Industry
- EDUC Consumer Specialties
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDUC Consumer Discretionary
- APRE Health Care
- Exchange
- EDUC Nasdaq
- APRE Nasdaq
- Market Cap
- EDUC 14.6M
- APRE 15.8M
- IPO Year
- EDUC N/A
- APRE 2019
- Fundamental
- Price
- EDUC $1.67
- APRE $3.62
- Analyst Decision
- EDUC
- APRE Strong Buy
- Analyst Count
- EDUC 0
- APRE 2
- Target Price
- EDUC N/A
- APRE $15.50
- AVG Volume (30 Days)
- EDUC 15.7K
- APRE 34.6K
- Earning Date
- EDUC 01-13-2025
- APRE 11-07-2024
- Dividend Yield
- EDUC N/A
- APRE N/A
- EPS Growth
- EDUC N/A
- APRE N/A
- EPS
- EDUC N/A
- APRE N/A
- Revenue
- EDUC $36,523,200.00
- APRE $1,310,839.00
- Revenue This Year
- EDUC N/A
- APRE $134.21
- Revenue Next Year
- EDUC N/A
- APRE N/A
- P/E Ratio
- EDUC N/A
- APRE N/A
- Revenue Growth
- EDUC N/A
- APRE 130.31
- 52 Week Low
- EDUC $1.36
- APRE $2.15
- 52 Week High
- EDUC $2.95
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- EDUC 43.24
- APRE 52.23
- Support Level
- EDUC $1.58
- APRE $3.34
- Resistance Level
- EDUC $1.78
- APRE $4.52
- Average True Range (ATR)
- EDUC 0.13
- APRE 0.40
- MACD
- EDUC 0.01
- APRE 0.01
- Stochastic Oscillator
- EDUC 38.10
- APRE 38.94
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.